Influenza vaccination: Lessons learned from the pandemic (H1N1) 2009 influenza outbreak

Mucosal Immunology

Volumn 3, Issue 5, 2010, Pages 422-424

  Openshaw, P J M ^a   Dunning, J ^a  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

INFLUENZA VACCINE; WART VIRUS VACCINE; WATER OIL CREAM;

CROSS PROTECTION; DISEASE SEVERITY; DOSE RESPONSE; DRUG FORMULATION; EPIDEMIC; GUILLAIN BARRE SYNDROME; HIGH RISK POPULATION; HUMAN; IMMUNE RESPONSE; INFECTION PREVENTION; INFLUENZA A (H1N1); INFLUENZA VACCINATION; INFLUENZA VIRUS A H1N1; MALARIA; MEDICAL RESEARCH; NOTE; PANDEMIC INFLUENZA; PAPILLOMAVIRUS INFECTION; PATIENT SAFETY; PREDICTION; PRIORITY JOURNAL; SEASONAL VARIATION; SINGLE DRUG DOSE; VIRUS CELL INTERACTION; VIRUS REPLICATION; VIRUS STRAIN; VIRUS TRANSMISSION;

EID: 77955880520     PISSN: 19330219     EISSN: None     Source Type: Journal    
DOI: 10.1038/mi.2010.34     Document Type: Note

References (14)

1. World Health Organisation. Pandemic (H1N1) 2009 - update 99, weekly update , http://www. who.int/csr/don/2010-05-07/en/index.html (accessed 05 May 2010)
2. Department of Health. Pandemic H1N1 (2009) Infl uenza: Chief Medical Offi cers Statistical Update, 15 April 2010 , http://www.dh.gov.uk/ prod-consum-dh/groups/dh-digitalasset/dh- 115427.pdf (accessed 05 May 2010)
3. Hospital Episode Statistics (HES), The NHS Information Centre for health and social care. Provisional monthly HES topic of interest: infl uenza , http://www.hesonline.nhs.uk/Ease/ servlet/ContentServer;jsessionid=wagtnz7841 ?siteID=1937 and categoryID=1243 (accessed 05 May 2010)
4. Department of Health. Infl uenza In Immunisation Against Infectious Disease 3rd edn (Salisbury, D., Ramsay, M. and Noakes, K., eds) 185-201 ( The Stationery Offi ce, London , 2006 , )
5. Note for Guidance on Harmonisation of Requirements for Infl uenza Vaccines. Committee for Proprietary Medicinal Products (CPMP). The European Agency for the Evaluation of Medicinal Products, Human Medicines Evaluation Unit. 12 March 1997 , http://www.ema.europa.eu/pdfs/human/ bwp/021496en.pdf (accessed 05 May 2010).
6. Macroepidemiology of Infl uenza Vaccination (MIV) Study Group. The macro-epidemiology of infl uenza vaccination in 56 countries, 1997 - 2 Vaccine 23 , 5133-5143 ( 2005 ).
7. Roman , F. , Vaman , T. , Gerlach , B. , Markendorf , A. , Gillard , P. and Devaster , J. M. Immunogenicity and safety in adults of one dose of infl uenza A H1N1v 2009 vaccine formulated with and without AS03A-adjuvant: preliminary report of an observer-blind, randomised trial. Vaccine 28 , 1740 - 1745 ( 2010 ).
8. World Health Organization (WHO). Options for the Use of Human H5N1 Infl uenza Vaccines and the WHO H5N1 Stockpile. WHO Scientifi c Consultation, 1-3 October 200 ( WHO, Scientifi c Geneva , 2007 )
9. Gar ç on , N. , Chomez , P. and Van Mechelen , M. GlaxoSmithKline adjuvant systems in vaccines: concepts, achievements and perspectives. Expert Rev. Vaccines 6 , 723-739 ( 2007 ).
10. Hancock , K. et al. Cross-reactive antibody responses to the 2009 pandemic H1N1 infl uenza virus. N. Engl. J. Med. 361 , 1945 - 1952 ( 2009 ).
11. Department of Health. Agreements secured for pre-pandemic vaccine for the UK. 15 May 2009 , http://www.dh.gov.uk/en/Publichealth/Flu/ Swinefl u/DH-09924 (accessed 05 May 2010)
12. Chan , Y. J. et al. Seroprevalence of antibodies to pandemic (H1N1) 2009 infl uenza virus among hospital staff in a medical center in Taiwan. J. Chin. Med. Assoc. 73 , 62 - 66 ( 2010 ).
13. Sencer , D. J. and Millar , J. D. Refl ections on the 1976 swine fl u vaccination program. Emerg. Infect Dis. 12 , 29 - 33 ( 2006 ).
14. Pfeifer , D. and Wood , D. Safety of pandemic vaccination. 6th WHO Meeting on Evaluation of Pandemic Infl uenza vaccines in Clinical Trials, Geneva, 18-19 February 201 http://www. who.int/vaccine-research/diseases/infl uenza/ meeting-18-19Feb2010/en/index1.html (accessed 05 May 2010